CTNM Contineum Therapeutics, Inc.

NASDAQ
$14.82

Contineum Therapeutics, Inc. (CTNM) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

Insider signal Moderately bearish Selling ran elevated versus CTNM's own trailing one-year pace, with 100% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 3 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
3
14 transactions
Purchases
$0
0 shares
Sales
$1.2M
79,062 shares
Net activity
-$1.2M
purchases less sales

How much of that selling was preplanned? 100% planned / 0% discretionary

10b5-1 plan sales $1.2M 14 transactions · 79,062 shares
Discretionary sales $0 0 transactions · 0 shares

Largest single sale: $462.3K.

Where they traded

Buy Sell Dot area is proportional to transaction value.

No open-market insider purchase on record.

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Stengone Carmine N. CEO and President Sell 10b5-1 2,500 $16.46 $41.1K 17,217 −12.7% of holding
Stengone Carmine N. CEO and President Sell 10b5-1 2,500 $16.01 $40.0K 17,217 −12.7% of holding
Lorrain Daniel S. Chief Scientific Officer Sell 10b5-1 25 $16.00 $400 135,202 −0% of holding
Stengone Carmine N. CEO and President Sell 10b5-1 2,500 $16.00 $40.0K 17,217 −12.7% of holding
Lorrain Daniel S. Chief Scientific Officer Sell 10b5-1 1,015 $16.00 $16.2K 135,202 −0.7% of holding
Lorrain Daniel S. 2 fills Chief Scientific Officer Sell 10b5-1 8,353 $15.84 $132.3K 137,703 −5.7% of holding
Lorrain Daniel S. Chief Scientific Officer Sell 10b5-1 28,826 $16.04 $462.3K 139,372 −17.1% of holding
Watkins Tim CMO & Head of Development Sell 10b5-1 10,833 $16.02 $173.6K 8,961 −54.7% of holding
Stengone Carmine N. CEO and President Sell 10b5-1 10,000 $16.01 $160.1K 17,217 −36.7% of holding
Lorrain Daniel S. Chief Scientific Officer Sell 10b5-1 4,170 $13.16 $54.9K 139,372 −2.9% of holding
Lorrain Daniel S. 2 fills Chief Scientific Officer Sell 10b5-1 4,170 $13.12 $54.7K 143,842 −2.8% of holding
Lorrain Daniel S. Chief Scientific Officer Sell 10b5-1 4,170 $13.43 $56.0K 147,712 −2.7% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.